We present a case of medulloblastoma metastatic to the pancreas in a 41-year-old woman with recurrent cerebellar medulloblastoma. On presentation, computed tomography of the abdomen and pelvis showed a 2.2 cm Â 2.6 cm hypodense pancreatic head mass associated with obstruction of the pancreatic duct. Endosonography with fine needle aspiration (EUS-FNA) was performed. Cytology showed a malignant small cell neoplasm that was consistent with medulloblastoma and was morphologically identical to the primary cerebellar medulloblastoma. Metastatic medulloblastoma to the pancreas is an extremely rare form of a secondary pancreatic tumor and very few case reports exist in the literature. The diagnosis rests on comparing cytological features when primary and secondary tumors are both available.
Introduction
Medulloblastoma may account for up to 20% of central nervous system (CNS) tumors in the pediatric population, which makes it the most common CNS malignancy in children. 1 However, this entity comprises only 0.4-1% of CNS neoplasms in adults. 2 It is usually restricted to the CNS, and metastases often occur along the neuroaxis. 3 Systemic (i.e., extraneural) metastasis is rare but portends a poor prognosis. Metastasis to the pancreas is relatively uncommon, and usually diagnosed at autopsy in association with extensive metastasis to other organ systems. 4, 5 We report a case of metastatic medulloblastoma involving the pancreas that was diagnosed by endosonography with fine needle aspiration (EUS-FNA) in a woman with recurrent medulloblastoma.
Case Report
In 2009, a 41-year old African-American woman was admitted to our hospital with worsening severe occipital headaches and neck and back pain associated with difficulty in maintaining balance. Magnetic resonance imaging (MRI) of the head, showed a contrast enhancing mass in the posterior fossa. The patient underwent bilateral suboccipital craniotomy with total resection of the tumor, but had no ventriculoperitoneal shunt placed. The pathology of the tumor was consistent with medulloblastoma. She postoperatively developed syndrome of inappropriate antidiuretic hormone secretion (SIADH). She continued to have difficulty in maintaining balance for which she had physical therapy. She subsequently underwent craniospinal radiation therapy with a plan to receive cisplatin and etoposide for three cycles, followed by eight cycles of cyclophosphamide and vincristine. However, 1 week into her radiation therapy, she developed severe intractable nausea, vomiting, mucositis associated with odynophagia, and dysphagia. She therefore lost 30 pounds. Because of her poor performance status, One month later, a repeat MRI scan to evaluate worsening dysarthria and ataxia showed progression of the disease. She was subsequently started on chemotherapy with cisplatin, etoposide, cyclophosphamide and carboplatin. A repeat MRI revealed progression of the disease with a significant increase in the size of the tumor. She then underwent a redo midline posterior fossa craniotomy for excision of the tumor; its pathology was consistent with recurrent medulloblastoma. This was complicated by a CSF leak from her incision, which required a repeat posterior fossa craniotomy to indirectly repair the CSF leak and to place a lumbar spinal drain. This was followed by intensity modulated radiation therapy to 40 Gy in 20 fractions.
Approximately 8 months later, she presented to the emergency center complaining of midepigastric pain with nausea and vomiting. Computerized tomography (CT) of the abdomen and pelvis showed a 2.2 cm Â 2.6 cm hypodense mass in the head of the pancreas and dilation of the pancreatic duct (Fig. 1) . She underwent EUS-FNA on the 2.3-cm heterogeneous mass, which contained multiple small anechoic spaces mixed with hyperechoic and hypoechoic areas in the head of the pancreas. The mass abutted the portal vein. Multiple hyperechoic strands with a lobular appearance were in the body and tail of pancreas (Figs. 2, 3) . Cytological smears and cell block sections with immunoperoxidase stains showed a malignant small cell neoplasm that represented an unusual high grade primary pancreatic neuroendocrine carcinoma or a metastatic medulloblastoma (Figs. 4, 5) . The absence of keratin expression and the close morphologic similarity between the pancreatic aspirate and the histologic sections of the patient's recurrent medulloblastoma favored metastatic medulloblastoma over a second primary high grade pancreatic neuroendocrine neoplasm. A positron emission tomography/CT scan showed multiple osseous metastases and metastatic disease to the proximal pancreas. Informed consent was obtained from the patient for this report.
Discussion
This is the first case of medulloblastoma with pancreatic metastasis diagnosed antemortem by EUS-FNA in the English literature. After glioblastoma and meningioma, medulloblastoma is the third most common CNS tumor to exhibit systemic metastases. In 1955, Weiss 6 proposed rigid criteria for diagnosing extracranial metastasis from primary CNS malignancies. These criteria include a single histologically characteristic CNS tumor, a clinical history indicating a primary CNS lesion, a complete postmortem examination to exclude peripheral primary tumor, and similar histological findings between the CNS and peripheral lesions. 6 In this patient, all of these criteria were fulfilled antemortem. After the initial diagnosis of medulloblastoma, the average interval to the development of extraneural metastasis is 18 months. In some patients, 13 years have elapsed after the initial diagnosis before metastasis developed. 7 Our patient, who had a high risk for metastasis, survived 3 years prior to being diagnosed. Osseous metastases (77%) are the most frequent site for extracranial spread in adults, followed by lymph nodes (33%) lungs (17%), muscle (13%), liver (10%), and the pleura. The spread of a primary CNS neoplasm extracranially occurs primarily by seeding via CSF pathway 8 (which gives rise to subdural subarachnoid metastasis 9, 10 ) and within the central canal of the spinal cord 5 via a hematogenous route or lymphatic route. Reports have also described spread by shunt tubing as a consequence of tumor cells escaping into the systemic circulation owing to the break in the blood-brain barrier. This potentially occurs as a result of tumor surgery with the insertion of a cerebrospinal shunt. 11, 12 Metastasis to the bone and pancreas in our patient made hematogeneous spread more likely. To our knowledge there are only five reported cases 4, 5, [13] [14] [15] in which medulloblastoma metastasized to the pancreas (Table 1 ). In four of these cases, the diagnosis was made at autopsy with metastasis to other systems. In one case report, the diagnosis was made antemortem by percutaneous needle biopsy. 4 In our patient with recurrent medulloblastoma, the diagnosis was made antemortem by EUS-FNA of the mass in the pancreas, which allowed detailed evaluation of the pancreas and acquisition of tissue diagnosis in one setting.
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